My laboratory has investigated the potential role of fetuin-A (also known as alpha 2HS glycoprotein) in tumor progression for the past 20 years. In 2013, we demonstrated and reported that fetuin-A drives the progression of head and neck squamous cell carcinomas. More recently a number of studies have indicated that fetuin-A is up-regulated in a number of solid tumors including pancreatic, breast and prostate tumors. We have now demonstrated (published data) that fetuin-A is a major driver of growth and metastasis in glioblastomas. We will soon embark on pre-clinical studies using mouse models for glioblastomas. This study is of immense interest to us and we would like to engage as many collaborators as possible. Currently our focus is to determine the mechanisms by which fetuin-A modifies adhesion and growth competent exosomes during tumor growth and metastasis. I am also interested in looking at the role of fetuin-A in prostate cancer progression. This disease disproportionately affects men of African descent.